TRIL - ALX Oncology Is A Promising CD47 Targeting Biotech With Massive Potential

• ALX Oncology enters into clinical trial collaboration agreement with Merck to use ALX148 in combination with Keytruda to treat patients with head and neck squamous cell carcinoma.
• It was shown that patients treated with the combination of ALX148 and Keytruda had achieved a 40% objective response rate.
• The global head and neck cancer market is expected to reach $4.5 billion by 2027.
• The CD47 blockade space is a sector that has been doing very well in treating cancer, but on the flip side, a lot of companies are targeting this space, like Gilead Sciences with Magrolimab and Trillium Therapeutics with TTI-621/TTI-622.

For further details see: